Athira Pharma, Inc. (NASDAQ:LONA) Stock Has Average Target Price of $17.33 According to Analysts

Shares of Athira Pharma, Inc. (NASDAQ:LONA) have been given an average rating of “Moderate Buy” by the six ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $17.33.

Several research analysts have commented on LONA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Athira Pharma in a research report on Friday, August 7th. Mizuho reduced their price objective on Athira Pharma from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 19th. Citizens Jmp decreased their target price on Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating for the company in a research report on Monday, August 17th. Finally, Wall Street Zen upgraded Athira Pharma to a “hold” rating in a research note on Saturday, October 17th.

Athira Pharma Price Performance

Shares of LONA stock opened at $4.94 on Friday. The firm has a market cap of $46.41 million, a P/E ratio of -1.17 and a beta of 2.11. Athira Pharma has a 1-year low of $2.21 and a 1-year high of $14.21. The firm’s 50-day simple moving average is $6.05 and its 200-day simple moving average is $7.57.

Athira Pharma (NASDAQ:LONA) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.20). Analysts expect that Athira Pharma will post -2.67 earnings per share for the current fiscal year.

Athira Pharma Company Profile

Athira Pharma is a clinical-stage biotechnology company focused on developing regenerative therapies for neurodegenerative diseases. Its research has centered on treatments intended to activate the hepatocyte growth factor pathway, which may support neuronal health, repair, and regeneration.

The company’s lead investigational product is fosgonimeton, formerly known as ATH-1017, an intravenous therapy developed for potential use in Alzheimer’s disease and other neurodegenerative conditions.